Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field
Pfizer is ending the commercialization of Beqvez, its hemophilia B gene therapy, according to multiple media reports. It marks an abrupt end for the gene therapy for the rare, inherited bleeding disorder. Pfizer gained ...
Pfizer is ending the commercialization of Beqvez, its hemophilia B gene therapy, according to multiple media reports.
It marks an abrupt end for the gene therapy for the rare, inherited bleeding disorder. Pfizer gained ...
